19
03, 2019
14
02, 2019
Lorenza Rimassa et al., Phase 2 study of tivantinib and cetuximab in KRAS wild-type metastatic colorectal cancer patients with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR/MET dual inhibition
Diatech Pharmacogenetics2020-01-22T12:34:32+01:00
15
11, 2018
9
11, 2018
9
10, 2018
1
10, 2018
31
07, 2018
26
06, 2018
19
06, 2018
2
06, 2018